logo

Neurosense Therapeutics Ltd. (NRSN)



Trade NRSN now with
  Date
  Headline
6/30/2022 8:37:15 AM NeuroSense Announces Positive Preliminary Results From Novel Alzheimer's Biomarker Study; Stock Up
6/27/2022 8:35:18 AM NeuroSense Therapeutics Reports Positive Results From Stage III ALS Biomarker Study; Stock Up
6/1/2022 8:32:41 AM NeuroSense Enrolls First Patient In Phase IIb ALS Trial For Combination Therapy PrimeC
5/31/2022 8:33:24 AM NeuroSense Therapeutics Q1 Net Loss $2.71 Mln Vs Net Loss Of $2.12 Mln Prior Year
4/11/2022 8:32:44 AM NeuroSense Therapeutics Commences Enrollment And Dosing In Pharmacokinetic Study Of PrimeC For ALS
3/21/2022 8:34:33 AM NeuroSense Therapeutics Receives FDA Clearance Of IND For PrimeC For Amyotrophic Lateral Sclerosis